Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 7/20 | 1.00 |
| ▸ | BRD2 | P25440 | 4/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 3/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 2/20 | 1.00 |
| ▸ | DNER | Q8NFT8 | 2/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | BRD1 | O95696 | 1/20 | 1.00 |
| ▸ | CCL2 | P13500 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 1/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 1/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881208 | 1.00 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881227 | 1.00 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21320191 | 0.93 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL15984904 | 0.93 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL29424160 | 0.92 | BRD4 (0.85) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL25727485 | 0.92 | BRD4 (0.85) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL30372667 | 0.92 | BRD4 (0.86) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21303807 | 0.92 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23317871 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21349526 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578943-A1 | METHOD FOR PRODUCING TARGE VIRUSES AND CULTURE COMPOSITION | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | claimed |
| US-20250188427-A1 | METHOD OF PRODUCING TARGET VIRUS AND CULTURE COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-06-12 | — | — | US | claimed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | claimed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | claimed |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2022-07-21 | — | — | US | claimed |
| US-11344546-B2 | Benzamide compounds | Recurium IP Holding, LLC (US) | 2022-05-31 | — | — | US | claimed |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | The Regents of the University of California, Davis (US) | 2021-06-01 | — | — | US | claimed |
| US-20210009543-A1 | BENZAMIDE COMPOUNDS | ZENO MANAGEMENT, INC. | 2021-01-14 | — | — | US | claimed |
| EP-3740487-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-25 | — | — | EP | claimed |
| EP-3737672-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-18 | — | — | EP | claimed |
| US-20180346988-A1 | ZNF532 FOR DIAGNOSIS AND TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-12-06 | — | — | US | claimed |
| US-20180325914-A1 | INCREASING STORAGE OF VITAMIN A, VITAMIN D AND/OR LIPIDS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-11-15 | — | — | US | claimed |
| US-10064798-B1 | Method for modulating pigmentation by targeting BET bromodomain proteins | THE UNIVERSITY OF TOLEDO (US) | 2018-09-04 | — | — | US | claimed |
| US-20180164317-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | US | claimed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | claimed |
| EP-3226898-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2017-10-11 | — | — | EP | claimed |
| US-20170007595-A1 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-12 | — | — | US | claimed |
| US-20160331760-A1 | INCREASING STORAGE OF VITAMIN A, VITAMIN D AND/OR LIPIDS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-11-17 | — | — | US | claimed |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2016-09-15 | — | — | US | claimed |
| WO-2016090219-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BRD4 24/4885BRDT 6/4885BRD2 33/4885 |
| US-20160331760-A1 | INCREASING STORAGE OF VITAMIN A, VITAMIN D AND/OR LIPIDS | VDR, BRD3, BRDT | BRD4 4/4885BRDT 3/4885BRD2 6/4885 |
| US-11020404-B2 | Use of CDK9 and BRD4 inhibitors to inhibit inflammation | CDK9, BRD4, CDK19 | BRD4 2/4885BRDT 51/4885BRD2 27/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | BRD4 2/4885BRDT 1/4885BRD2 4/4885 |
| US-20170007595-A1 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | NSD3, NSD2, BRD3 | BRD4 5/4885BRDT 11/4885BRD2 15/4885 |
| US-20180164317-A1 | METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS | MITF, TFAM, POLRMT | BRD4 20/4885BRDT 221/4885BRD2 88/4885 |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BRD4 24/4885BRDT 6/4885BRD2 33/4885 |
| US-20210009543-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BRD4 24/4885BRDT 6/4885BRD2 33/4885 |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885BRDT 4024/4885BRD2 4149/4885 |
| US-11344546-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BRD4 24/4885BRDT 6/4885BRD2 33/4885 |
| US-10064798-B1 | Method for modulating pigmentation by targeting BET bromodomain proteins | TYR, BET1, MITF | BRD4 6/4885BRDT 7/4885BRD2 8/4885 |
| US-20180325914-A1 | INCREASING STORAGE OF VITAMIN A, VITAMIN D AND/OR LIPIDS | VDR, BRD3, BRDT | BRD4 4/4885BRDT 3/4885BRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.